MALDI Mass Spectrometry Imaging of Erlotinib Administered in Combination With Bevacizumab in Xenograft Mice Bearing B901L, EGFR-mutated NSCLC Cells

Scientific Reports - United Kingdom
doi 10.1038/s41598-017-17211-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MALDI Mass Spectrometry Imaging of Neuronal Cell Cultures

Journal of the American Society for Mass Spectrometry
Structural BiologySpectroscopy
2011English

Stretched Tissue Mounting for MALDI Mass Spectrometry Imaging

Analytical Chemistry
Analytical Chemistry
2011English

P2.01-06 HSP72 Expression Associates With Survival in EGFR Mutated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA27.03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC

Cancer Discovery
Oncology
2016English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Evaluation of Therapeutics in Three-Dimensional Cell Culture Systems by MALDI Imaging Mass Spectrometry

Analytical Chemistry
Analytical Chemistry
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy